Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

BMJ Open

Volumn 2, Issue 5, 2012, Pages

  Clar, Christine ^a   Gill, James Alexander ^b,c   Court, Rachel ^b   Waugh, Norman ^b  

^a Systematic Review   (Germany)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BONE DENSITY; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84869745717     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001007     Document Type: Article

References (22)

1. Diabetes UK. Diabetes in the UK: key statistics on diabetes. http://www.diabetes.org.uk/Documents/Reports/Diabetes-in-the-UK-2010.pdf. 2010. (accessed 2 Aug 2012).
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9.
3. Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989;14:49-57.
4. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-82.
5. Hanefeld M, Forst T. Dapagliflozin, an SGLT2 inhibitor, for diabetes. Lancet 2010;375:2196-8.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). 2011. The Cochrane Collaboration. (accessed 9 Aug 2012).
7. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. WHO/NCD/NCS/99.2. 1999. http://whqlibdoc.who.int/hq/1999/who-ncd-ncs-99.2.pdf. (accessed 9 Aug 2012).
8. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33.
9. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31.
10. Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990-9.
11. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011;34:2015-22.
12. Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473-8.
13. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38.
14. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-62.
15. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:405-15.
16. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8.
17. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6.
18. Del Prato S, Nauck MA, Rohwedder K, et al. Long-term efficacy and safety of dapagliflozin vs add-on glipizide in patients with type 2 diabetes inadequately controlled with metformin: 2 year results. A 47th Annual Meeting of the European Association for the Study of Diabetes 2011; Lisbon, Portugal. S348.
19. Wilding J, Woo V, Rohwedder K, et al. Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin. A 72nd Scientific Session of the American Diabetes Association 2012; Philadelphia, USA. A267-8.
20. Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010;14:1-248.
21. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93.
22. Food and Drug Administration. Summary minutes of the endocronologic and metabolic drugs advisory committee. 2011. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262990.pdf. (accessed 9 Aug 2012).